NTRK activation in cancer is more than fusions
TRK inhibitors have had some of the most remarkable clinical impacts for patients with tumours driven by oncogenic gene fusions in the TRK genes. But are there other structural variants involving the TRKs that drive cancer? Can these also be targeted by TRK inhibitors?